Out of a total of 5,224 patients enrolled in the study, researchers concluded “no significant difference between clindamycin and TMP-SMX, with respect to either efficacy or side-effect profile.”
The original study can be found here.
More articles on ASC issues:
How ASCs fit into population health: Where are the best opportunities?
4 recent ASC industry leadership moves – March 19, 2015
Hospitals in the ASC market: Sorting out the rivals from the potential partners
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
